Search alternatives:
largest decrease » largest decreases (Expand Search), marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
mean decrease » a decrease (Expand Search)
largest decrease » largest decreases (Expand Search), marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
mean decrease » a decrease (Expand Search)
-
7761
-
7762
-
7763
-
7764
S3 File -
Published 2024“…Sex-specific hemoglobin normalization at week 16 occurred in 40.0% (2 of 5) (PADDOCK), 62.5% (5 of 8) (PRINCE), and 63.6% (7 of 11) (PEGASUS). In all studies, mean ARCs decreased from above normal to normal and ARC normalization increased. …”
-
7765
S2 File -
Published 2024“…Sex-specific hemoglobin normalization at week 16 occurred in 40.0% (2 of 5) (PADDOCK), 62.5% (5 of 8) (PRINCE), and 63.6% (7 of 11) (PEGASUS). In all studies, mean ARCs decreased from above normal to normal and ARC normalization increased. …”
-
7766
Overview of the post hoc analysis.
Published 2024“…Sex-specific hemoglobin normalization at week 16 occurred in 40.0% (2 of 5) (PADDOCK), 62.5% (5 of 8) (PRINCE), and 63.6% (7 of 11) (PEGASUS). In all studies, mean ARCs decreased from above normal to normal and ARC normalization increased. …”
-
7767
S1 File -
Published 2024“…Sex-specific hemoglobin normalization at week 16 occurred in 40.0% (2 of 5) (PADDOCK), 62.5% (5 of 8) (PRINCE), and 63.6% (7 of 11) (PEGASUS). In all studies, mean ARCs decreased from above normal to normal and ARC normalization increased. …”
-
7768
Cox analysis.
Published 2025“…Survival was 97.5% at 48 hours, 85% at 7 days, 62% at 14 days, and 16.3% at the end of the study. Variables decreasing survival in patients with COVID-19 who were users of NFVC were age ≥ 60 years (HR = 2.23; 95% CI: 1.21–4.08), presence of arterial hypertension (HR = 1.87; 95% CI: 1.01–3.45), increased work of breathing on hospital admission (HR = 2.38; 95% CI: 1.31–4.35), and a ROX index (iROX) < 3.85 (HR = 1.71; 95% CI: 1.01–2.93).…”
-
7769
-
7770
Meta-analytical results of secondary outcomes.
Published 2023“…</p><p>Results</p><p>Twenty-three RCTs (mean dosage 5mg to 300mg amitriptyline/day) and 4217 patients (mean age 40.3 years) were included. …”
-
7771
Study characteristics.
Published 2023“…</p><p>Results</p><p>Twenty-three RCTs (mean dosage 5mg to 300mg amitriptyline/day) and 4217 patients (mean age 40.3 years) were included. …”
-
7772
Forest plots of primary outcomes.
Published 2023“…</p><p>Results</p><p>Twenty-three RCTs (mean dosage 5mg to 300mg amitriptyline/day) and 4217 patients (mean age 40.3 years) were included. …”
-
7773
-
7774
-
7775
-
7776
-
7777
-
7778
-
7779
-
7780
Characteristics of JIA patients.
Published 2025“…Twelve studies published between 2003 and 2018 were analyzed, encompassing 1513 patients with a mean age of 11.4 years. Tumor necrosis factor alpha inhibitors were the predominant biologic agents used (75.8%), with a mean follow-up duration of 2 years post-biologic therapy initiation. …”